Climate Change Data

Xspray Pharma AB (publ)

Climate Impact & Sustainability Data (2022)

Reporting Period: 2022

Environmental Metrics

ESG Focus Areas

  • Good health and well-being
  • Environmental impact minimization (energy efficiency, waste reduction)
  • Responsible procurement and supply chain management
  • Employee well-being and development
  • Regulatory compliance

Environmental Achievements

  • Use of clean carbon dioxide in production process

Social Achievements

  • Increased number of employees from 23 to 27
  • Continued recruitment of key competencies
  • Strengthening of company culture
  • Implementation of an employee introductory program
  • Focus on gender equality and diversity in recruitment

Governance Achievements

  • Full compliance with the Swedish Code of Corporate Governance
  • Establishment of a Remuneration Committee and an Audit Committee
  • Annual self-assessment of the Board of Directors’ performance
  • Implementation of long-term incentive programs

Climate Goals & Targets

Medium-term Goals:
  • Net sales exceeding USD 400 million by 2030
  • Profit margin exceeding 65 percent by 2030
  • 5 commercialized products by 2030
  • 3 product candidates in development by 2030
Short-term Goals:
  • Complete pivotal clinical studies for XS003 by 2023

Environmental Challenges

  • Lawsuit filed by Bristol Myers Squibb for patent infringement related to XS004
  • Financing risk due to pre-commercial stage and high development costs
  • Potential delays in development and regulatory approvals
Mitigation Strategies
  • Active reinforcement of patent portfolio
  • Monitoring cash flow and evaluating financing options (including capital raises)
  • Partnership with EVERSANA for commercialization of XS004
  • Focus on efficient development processes to reduce costs and timelines

Supply Chain Management

Responsible Procurement
  • Sustainability requirements on suppliers, CMOs, and collaboration partners
  • Preference for environmentally friendly inputs, processes, and transportation
  • Use of local suppliers where possible

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: Swedish Code of Corporate Governance, IFRS

Third-party Assurance: KPMG AB

UN Sustainable Development Goals

  • SDG 3: Good Health and Well-being

Development of improved cancer treatments

Sustainable Products & Innovation

  • Improved versions of marketed PKIs with enhanced patient benefits